Related Experiment Videos
[Long-term management of post acute coronary syndrome with oral antiplatelet therapy]
1Service de cardiologie, CHU Bocage, boulevard Mal de Lattre de Tassigny, Dijon, France.
Insights
Dual antiplatelet therapy with clopidogrel and aspirin is recommended for acute coronary syndrome (ACS) but remains underused. Real-world data show this underuse negatively impacts patient morbidity and mortality.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Cardiovascular disease is a leading cause of mortality globally.
- Coagulation inhibitors are crucial in managing acute coronary syndromes (ACS).
- Dual antiplatelet therapy (DAPT) with clopidogrel and aspirin is the gold standard for ACS management.
Purpose of the Study:
- To highlight the underutilization of recommended DAPT in ACS.
- To underscore the negative real-world impact of suboptimal antiplatelet therapy.
Main Methods:
- Analysis of national and international registries.
- Review of clinical practice data for ST-elevation and non-ST-elevation ACS.
Main Results:
- Despite Class I recommendations, DAPT with clopidogrel and aspirin is underprescribed.
- Failure to prescribe DAPT is associated with increased morbidity and mortality in ACS patients.
- A significant gap exists between evidence-based guidelines and clinical practice.
Conclusions:
- The underuse of DAPT in ACS management poses a significant public health challenge.
- Bridging the gap between randomized trial results and real-world application is critical for improving ACS outcomes.
Abstract:
Cardiovascular disease is the primary cause of early death and morbidity in the industrialized world and is becoming a growing problem in many developing countries. Coagulation inhibitors play a major role in the management of the acute phase of ACS whether in association with reperfusion strategies or not. Currently, and in accordance with the results of major randomised studies, for medium and long-term management, the association of Clopidogrel and aspirin is the treatment of choice. However, despite the recognised benefits of this therapeutic strategy and above all the recommendations of learned societies, which have placed this bi-therapy in class I, according to national and international registries it is still underused. Moreover, all of these registries have confirmed, in the real world, the negative impact of not prescribing this antiplatelet therapy on morbidity and mortality after both ST and non-ST elevation acute coronary syndrome. which shows the difficulty of applying to everyday clinical practice the results of major randomised cohorts.
Related Concept Videos
Acute Coronary Syndrome IV: Interprofessional Care
Coronary Artery Disease V: Interprofessional Care
Atherosclerosis III: Management
Angina IV: Management
Peripheral Artery Disease III: Interprofessional Care
Acute Coronary Syndrome V: Nursing Management